Particularly well-described skin AEs of melanoma treatments include lichenoid immune-related cutaneous adverse events (ircAE), associated with PD-1/PD-L1 blockade [13], as well as acneiform rashes related to MEK inhibition [12]. This evidence concerns the gene MAP2K7 and melanoma.